Acorda Therapeutics Inc.

4.72-0.0100-0.21%Vol 2.65K1Y Perf -27.10%
Apr 23rd, 2021 09:35 DELAYED
BID4.71 ASK4.74
Open4.75 Previous Close4.73
Pre-Market4.81 After-Market-
 0.08 1.69%  - -
Target Price
17.50 
Analyst Rating
Hold 3.00
Potential %
273.93 
Finscreener Ranking
★★★     49.84
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★     47.84
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     33.08
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap44.79M 
Earnings Rating
Neutral
Price Range Ratio 52W %
29.96 
Earnings Date
4th May 2021

Today's Price Range

4.684.75

52W Range

2.539.84

5 Year PE Ratio Range

-18.10174.50

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
12.89%
1 Month
-11.26%
3 Months
-37.76%
6 Months
466.40%
1 Year
-27.10%
3 Years
-79.74%
5 Years
-84.30%
10 Years
-82.84%

TickerPriceChg.Chg.%
ACOR4.72-0.0100-0.21
AAPL132.870.93000.70
GOOG2 288.1520.23000.89
MSFT258.321.15000.45
XOM55.460.19000.34
WFC42.850.15000.35
JNJ164.34-0.8400-0.51
FB299.072.55000.86
GE13.430.02000.15
JPM147.620.25000.17
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.60
0.44
1.13
-2.50
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
78.10
-50.40
-23.40
-83.00
-75.86
RevenueValueIndustryS&P 500US Markets
124.87M
13.16
-38.55
-23.14
Earnings HistoryEstimateReportedSurprise %
Q04 2020-2.579.82482.10
Q03 2020-2.820.30110.64
Q02 2020-3.84-2.2242.19
Q01 2020-3.36-0.8475.00
Q04 2019-3.78-1.2068.25
Q03 2019-3.96-3.1221.21
Q02 2019-1.18-0.6544.92
Q01 2019-1.07-0.6242.06
Earnings Per EndEstimateRevision %Trend
3/2021 QR-3.71-7.54Negative
6/2021 QR-2.7625.00Positive
12/2021 FY-12.1716.70Positive
12/2022 FY-7.7413.33Positive
Next Report Date4th May 2021
Estimated EPS Next Report-3.71
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume2.65K
Shares Outstanding9.49M
Trades Count38
Dollar Volume1.29M
Avg. Volume862.11K
Avg. Weekly Volume173.65K
Avg. Monthly Volume165.19K
Avg. Quarterly Volume271.76K

Acorda Therapeutics Inc. (NASDAQ: ACOR) stock closed at 4.73 per share at the end of the most recent trading day (a 2.83% change compared to the prior day closing price) with a volume of 159.23K shares and market capitalization of 44.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 344 people. Acorda Therapeutics Inc. CEO is Ron Cohen.

The one-year performance of Acorda Therapeutics Inc. stock is -27.1%, while year-to-date (YTD) performance is 585.41%. ACOR stock has a five-year performance of -84.3%. Its 52-week range is between 2.53 and 9.84, which gives ACOR stock a 52-week price range ratio of 29.96%

Acorda Therapeutics Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 0.17, a price-to-sale (PS) ratio of 0.32, a price to cashflow ratio of 7.40, a PEG ratio of 2.32, a ROA of -13.25%, a ROC of 11.12% and a ROE of -34.56%. The company’s profit margin is -75.86%, its EBITDA margin is -23.40%, and its revenue ttm is $124.87 Million , which makes it $13.16 revenue per share.

Of the last four earnings reports from Acorda Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-3.71 for the next earnings report. Acorda Therapeutics Inc.’s next earnings report date is 04th May 2021.

The consensus rating of Wall Street analysts for Acorda Therapeutics Inc. is Hold (3), with a target price of $17.5, which is +273.93% compared to the current price. The earnings rating for Acorda Therapeutics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acorda Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acorda Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.42, ATR14 : 0.50, CCI20 : 31.62, Chaikin Money Flow : -0.01, MACD : -0.52, Money Flow Index : 49.26, ROC : -1.46, RSI : 51.10, STOCH (14,3) : 80.00, STOCH RSI : 1.00, UO : 57.40, Williams %R : -20.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acorda Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (66.67 %)
4 (66.67 %)
4 (66.67 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Acorda Therapeutics Inc.

Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.

CEO: Ron Cohen

Telephone: +1 914 347-4300

Address: 420 Saw Mill River Road, Ardsley 10502, NY, US

Number of employees: 344

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

48%52%

Bearish Bullish

58%42%

Bearish Bullish

61%39%

News

Stocktwits